SCHEMBL6896159

SCHEMBL6896159

CCCc1ccc(C)c(OC(=O)OC(C)I)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.40
ACHE P22303 2/20 0.39
ALOX15 P16050 3/20 0.38
NPC1 O15118 3/20 0.37
RAB9A P51151 3/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
MAPK1 P28482 1/20 0.37
PPARG P37231 1/20 0.36
PPARA Q07869 1/20 0.36
ADRB2 P07550 1/20 0.36
ADRA2A P08913 1/20 0.36
DRD2 P14416 1/20 0.36
ADRA2C P18825 1/20 0.36
DRD1 P21728 1/20 0.36
ADRA1A P35348 1/20 0.36
DRD3 P35462 1/20 0.36
ACACB O00763 3/20 0.36
BCHE P06276 1/20 0.35
THRB P10828 1/20 0.35
NCEH1 Q6PIU2 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6890813 0.80 TSHR (0.43) ACHESMN1; SMN2PPARGPPARAADRA1A
SCHEMBL6693077 0.78 ACHE (0.53) PKMACHENPC1RAB9ASMN1; SMN2
SCHEMBL6896154 0.77 TYR (0.49) ACHEBCHE
SCHEMBL6893852 0.73 THRA (0.44) PPARGPPARAADRA2AADRA2CTHRB
SCHEMBL6892954 0.73 TDP1 (0.44) SMN1; SMN2PPARGBCHEALDH1A1
SCHEMBL6890949 0.71 L3MBTL1 (0.47) SMN1; SMN2ALDH1A1MAPT
SCHEMBL2563160 0.70 NPC1 (0.55) NPC1RAB9ASMN1; SMN2MAPK1ALDH1A1
SCHEMBL14290044 0.70 BCHE (0.44) ACHENPC1RAB9ASMN1; SMN2MAPK1
SCHEMBL2559405 0.69 ATM (0.48) NPC1RAB9ASMN1; SMN2MAPK1PPARG
SCHEMBL25299267 0.69 NPC1 (0.56) NPC1RAB9ASMN1; SMN2MAPK1PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6677331-B2 HAVING SUBSTITUTED IMIDAZO(5,1-B)THIAZOLE GROUP AT 2-POSITION; MICROBIOCIDES AGAINST BETA-LACTAMASE PRODUCING BACTERIA AND RESISTANT PSEUDOMONAS MEIJI SEIKA KAISHA, LTD. (JP) 2004-01-13 US disclosed
US-20030149016-A1 Novel carbapenem derivatives KANO YUKO (JP) 2003-08-07 US disclosed
US-6458780-B1 IMIDAZO(5,1-B)THIAZOLE GROUP AT THE 2-POSITION ON THE CARBAPENEM RING HAVE HIGH ANTI-MICROBIAL ACTIVITIES AGAINST .BETA.-LACTAMASE PRODUCING BACTERIA, MRSA, RESISTANT-PSEUDOMONAS AERUGINOSA, PRSP, ENTEROCOCCI, AND MEIJI SEIKA KAISHA, LTD. (JP) 2002-10-01 US disclosed
EP-1101766-A1 NOVEL CARBAPENEM DERIVATIVES MEIJI SEIKA KAISHA LTD. (JP) 2001-05-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149016-A1 Novel carbapenem derivatives DPEP1, TMPRSS15, STK35 PKM 1070/4885ACHE 3979/4885ALOX15 2514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.